JAK1 and anemia: Momelotinib is a JAK1/2 inhibitor as well as a type 1 activin receptor (ACVR1) inhibitor being evaluated in MF patients with anemia on the premise that ACVR1 inhibition regulates hepcidin levels to restore iron homeostasis and improve anemia [66].